We are live on ! Find out more
CHB

Global X China Biotech Innovation ETF
CHB

Delisted

CHB was delisted on the 16th of February, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Global X China Biotech Innovation ETF in 2024 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $373K → $0 (-$373K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
–
Holders Change
-3
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$197K
2
Jane Street
Jane Street
New York
-$176K
3
UBS Group
UBS Group
Switzerland
-$186
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
– -$197K -24,314 Closed
Jane Street
2
Jane Street
New York
– -$176K -21,688 Closed
UBS Group
3
UBS Group
Switzerland
– -$186 -23 Closed

CHB Hedge Fund Activity: Q1 2024 in Review

0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q1 2024, worth a combined $0 — down 100% from $373K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CHB and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Citadel Advisors, exiting entirely with an estimated $197K sold.

  • 0 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q1 2024, down from 3 in Q4 2023.
  • Funds reported $0 of Global X China Biotech Innovation ETF stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Global X China Biotech Innovation ETF positions in Q1 2024 and 3 closed out, a net change of -3 holders.
  • The largest Global X China Biotech Innovation ETF seller in Q1 2024 was Citadel Advisors, an estimated $197K sold.

Based on aggregated 13F filings for Q1 2024.